Efficacy

For adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine*

TRODELVY CAN HELP SHRINK YOUR TUMORS

  • TRODELVY was studied in 112 adults with bladder cancer and cancers of the urinary tract that spread or could not be removed by surgery who have received a platinum-containing chemotherapy medicine and an immunotherapy medicine
  • Patients were given TRODELVY 10 mg/kg as an intravenous infusion on Days 1 and 8 of a 21-day treatment cycle

*TRODELVY is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.

TRODELVY® (sacituzumab govitecan-hziy) results chart, tumor shrinking, length of response

TRODELVY was studied across a range of patients

  • The median age was 66 years (range 33-90 years)
  • The majority of patients were male (78%) and White (74%)
  • 96% of patients had metastatic disease; 67% had visceral metastases, including 34% with liver metastases
  • The median number of prior therapies for advanced cancer was 3 (range 1–8)